公司信息

伊普诺康司是一家集研发、生产、销售、服务为一体的***高新技术企业，自创司以来，一直致力于做精做专生化产业，不断完善自己的产业基地。公司现有注册产品76项，涵盖肝功能类、肾功能类、心肌标志物类、血脂类、糖代谢类、特种蛋白类、肿瘤类等品类。随着体外诊断市场的不断细分和发展，公司正快速向POCT、免疫诊断、分子诊断等领域进军。与此同时，公司自主研发的伊普诺康品牌生化仪即将投产。创新生物科技，增进人类福祉。公司本着“诚信立足，创新取胜，以人为本，共赢共荣”的经营理念，始终贯彻求真务实，精益求精的思想，新辟大型现代化厂房，建设高端试剂产业化基地，引进先进生产设备，以雄厚的技术力量为依托，以严格的生产管理和品质控制为基础，以领先的销售模式和完善的市场布局为保证，创立了一套科学有效的营销服务体系，为您提供最专业的服务。“行远必自逊，追求无止境”，2016年1月，公司完成“新三板”挂牌（股票代码：835852），标志着公司在引进战略资本做大做强的道路上迈出了实质性的步伐。伊普诺康将以“新三板”上市为契机，恒久不辍地助力体外诊断事业，为中国检验医学的发展贡献力量！Anhui Iprocom biotechnology Co., Ltd, (Iprocom) is a state-level high-tech enterprise which integrates research, manufacture and marketing. We are committed to make our company more sophisticated and more professional in biochemistry industry, and to constantly perfect our own industrial base. Iprocom has 76 registered products up to now. These products encompass a wide range of medical uses such as liver function, renal function, cardiac bio-markers, glycometabolism, special proteins and tumor etc. with the development and subdivision of In Vitro？Diagnostics market, Iprocom is speedily coming into the field of POCT, immunologic diagnosis and molecular diagnosis. Meanwhile, Iprocom self-developed biochemical analyzer will soon go into production.Innovation in biotechnology will inevitably benefit the welfare of all human beings. Iprocom sticks to the management ideas of “honesty as foothold, triumph with innovation, people comes first” and is persistent with pragmatism and the spirit of striving for perfection. Furthermore, we have built a number of large-scale modernized plants, reinforced our high-end industrialized base for reagents, and introduced advanced production equipment from abroad. We will rely on strong technical power, based on rigorous management rules and quality control, guaranteed by advanced sales models and perfect market layout, founding a set of scientific and effective marketing service system, in order to provide the most professional service for you!“Modesty leads to progress and there is no limit to exploration”. January 2016, our company has completed the “Three new board” listing （Stock code：835852）, which marks an essential step forward to being stronger by drawing on strategic capitals. We are going to take this opportunity to consistently support our in vitro diagnostic cause and make our contribution to the development of China’s diagnostic medical science.